FS Development Corporati... Aktie - FSII

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

9,80

Gebot

9,77

Fragen

9,87

Volumen

0,00 Tagesbereich 0,00

0,00 52-Wochen-Bereich 0,00

Handelsende

9,80

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

Finanzvolumen

VWAP

Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19

Ongoing Phase I trial shows potential for stand-alone, unboosted agent against COVID-19 Gross proceeds made...

FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections

Proposed merger heads to shareholder vote on December 23rd as ongoing Phase I trial shows potential for unboosted oral regimen In advance of the...

FS Development Corp. II Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021

FS Development Corp. II, a Delaware corporation (the “Company”) (Nasdaq: FSII), announced today that its registration statement on Form S-4 (File...

Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 Infections

CARLSBAD, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical-stage...

Pardes Biosciences Appoints Deborah M. Autor, J.D. and Laura J. Hamill to Board of Directors

CARLSBAD, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., an early-stage...

Pardes Biosciences & FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Adv...

Leading institutional and strategic investors commit $75 million through a common stock private investment in public equity (“PIPE”) led by...

FS Development Corp. II, Sponsored by Foresite Capital, Announces Pricing of Upsized $175 Million Initial Public Offering

FS Development Corp. II (the “Company”) announced today that it priced its initial public offering of 17,500,000 shares of Class A common stock...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

FSII - Frequently Asked Questions (FAQ)

What is the current FS Development Corporati... share price?

The current share price of FS Development Corporati... is US$ 9,80

What is the 1 year trading range for FS Development Corporati... share price?

FS Development Corporati... has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
SUNESUNation Energy Inc	US$ 0,4944 (179,16%)	180,74M
BTOGBit Origin Ltd	US$ 0,4809 (71,75%)	14,53M
HFBLHome Federal Bancorp Inc of Louisiana	US$ 19,85 (53,88%)	5
BBGIBeasley Broadcast Group Inc	US$ 9,99 (53,46%)	37
VTVTvTv Therapeutics Inc	US$ 25,00 (49,88%)	4
SYRESpyre Therapeutics Inc	US$ 13,01 (-36,54%)	70
LUNRIntuitive Machines Inc	US$ 7,20 (-36,06%)	4,41M
ACXPAcurx Pharmaceuticals Inc	US$ 0,432 (-33,74%)	83,07k
PROVProvident Financial Holdings Inc	US$ 11,20 (-24,78%)	18
USCBUSCB Financial Holdings Inc	US$ 14,20 (-20,89%)	12
SUNESUNation Energy Inc	US$ 0,4944 (179,16%)	180,74M
FAMIFarmmi Inc	US$ 0,31 (35,61%)	44,69M
PSTVPlus Therapeutics Inc	US$ 1,94 (34,72%)	29,15M
CTMXCytomX Therapeutics Inc	US$ 0,7213 (16,85%)	25,03M
ICONIcon Energy Corporation	US$ 0,1755 (21,03%)	24,65M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

FS Development Corporation II (FSII)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

FSII Neueste Nachrichten

Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19

FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections

FS Development Corp. II Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021

Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 Infections

Pardes Biosciences Appoints Deborah M. Autor, J.D. and Laura J. Hamill to Board of Directors

Pardes Biosciences & FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Adv...

FS Development Corp. II, Sponsored by Foresite Capital, Announces Pricing of Upsized $175 Million Initial Public Offering

Tokyo Electron Limited Completes Acquisition of FSI International, Inc.

Tokyo Electron Limited Announces Completion of Tender Offer for FSI International, Inc.

Tokyo Electron Limited Extends Tender Offer to Acquire FSI International, Inc.

FSII - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

FS Development Corporation II (FSII) Börsenkurse

FS Development Corporation II (FSII)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

FSII Neueste Nachrichten

Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19

FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections

FS Development Corp. II Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021

Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 Infections

Pardes Biosciences Appoints Deborah M. Autor, J.D. and Laura J. Hamill to Board of Directors

Pardes Biosciences & FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Adv...

FS Development Corp. II, Sponsored by Foresite Capital, Announces Pricing of Upsized $175 Million Initial Public Offering

Tokyo Electron Limited Completes Acquisition of FSI International, Inc.

Tokyo Electron Limited Announces Completion of Tender Offer for FSI International, Inc.

Tokyo Electron Limited Extends Tender Offer to Acquire FSI International, Inc.

FSII - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS